Verastem (NASDAQ:VSTM) issued its earnings results on Tuesday. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.01), Yahoo Finance reports.
Verastem (NASDAQ:VSTM) traded down $0.02 during trading on Wednesday, hitting $3.34. 243,246 shares of the stock traded hands, compared to its average volume of 676,561. The company has a market capitalization of $171.71, a PE ratio of -2.04 and a beta of 2.25. Verastem has a 52-week low of $1.37 and a 52-week high of $5.71. The company has a current ratio of 3.12, a quick ratio of 3.12 and a debt-to-equity ratio of 0.06.
A number of equities research analysts have issued reports on VSTM shares. Cantor Fitzgerald reissued a “buy” rating and set a $17.00 target price on shares of Verastem in a report on Wednesday, February 7th. Cann reissued a “buy” rating and set a $13.00 target price on shares of Verastem in a report on Friday, January 26th. Oppenheimer set a $13.00 target price on shares of Verastem and gave the company a “buy” rating in a report on Thursday, December 21st. HC Wainwright set a $10.00 target price on shares of Verastem and gave the company a “buy” rating in a report on Wednesday, December 13th. Finally, Raymond James Financial reissued a “buy” rating on shares of Verastem in a report on Monday, December 11th. One research analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company’s stock. Verastem currently has a consensus rating of “Buy” and an average target price of $10.14.
WARNING: This story was originally posted by Ticker Report and is the property of of Ticker Report. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/3262059/verastem-vstm-announces-earnings-results.html.
Verastem Company Profile
Verastem, Inc is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584.
Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.